BR112023021046A2 - Composições e métodos para tratamento de miastenia grave pediátrica - Google Patents

Composições e métodos para tratamento de miastenia grave pediátrica

Info

Publication number
BR112023021046A2
BR112023021046A2 BR112023021046A BR112023021046A BR112023021046A2 BR 112023021046 A2 BR112023021046 A2 BR 112023021046A2 BR 112023021046 A BR112023021046 A BR 112023021046A BR 112023021046 A BR112023021046 A BR 112023021046A BR 112023021046 A2 BR112023021046 A2 BR 112023021046A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
pediatric
treatment
myasthenia
Prior art date
Application number
BR112023021046A
Other languages
English (en)
Portuguese (pt)
Inventor
Shawn Black
Sindhu Ramchandren
Yaowei Zhu
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of BR112023021046A2 publication Critical patent/BR112023021046A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112023021046A 2021-04-12 2022-04-12 Composições e métodos para tratamento de miastenia grave pediátrica BR112023021046A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163173919P 2021-04-12 2021-04-12
US202163219155P 2021-07-07 2021-07-07
US202263266880P 2022-01-18 2022-01-18
PCT/US2022/024354 WO2022221239A1 (en) 2021-04-12 2022-04-12 Compositions and methods for treating pediatric myasthenia gravis

Publications (1)

Publication Number Publication Date
BR112023021046A2 true BR112023021046A2 (pt) 2023-12-19

Family

ID=83640966

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023021046A BR112023021046A2 (pt) 2021-04-12 2022-04-12 Composições e métodos para tratamento de miastenia grave pediátrica

Country Status (13)

Country Link
US (1) US20240182598A1 (cg-RX-API-DMAC7.html)
EP (1) EP4323002A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024517087A (cg-RX-API-DMAC7.html)
KR (1) KR20230169207A (cg-RX-API-DMAC7.html)
AU (1) AU2022256389A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021046A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216642A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003033A1 (cg-RX-API-DMAC7.html)
IL (1) IL307445A (cg-RX-API-DMAC7.html)
JO (1) JOP20230247A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012032A (cg-RX-API-DMAC7.html)
PH (1) PH12023552841A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022221239A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019001806A2 (pt) 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
EA202190264A1 (ru) 2018-07-20 2021-05-20 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101540823B1 (ko) * 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
JP6853178B2 (ja) * 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド FcRn抗体およびその使用方法
MA51032A (fr) * 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
BR112020011310A2 (pt) * 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
EP3762027A4 (en) * 2018-02-13 2022-06-15 The Brigham & Women's Hospital, Inc. THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES
IL280280B2 (en) * 2018-07-20 2024-11-01 Momenta Pharmaceuticals Inc Compositions of fcrn antibodies and methods of use thereof
JP7518821B2 (ja) * 2018-10-16 2024-07-18 ユーシービー バイオファルマ エスアールエル 重症筋無力症の治療方法

Also Published As

Publication number Publication date
AU2022256389A9 (en) 2023-12-07
KR20230169207A (ko) 2023-12-15
JOP20230247A1 (ar) 2023-10-12
MX2023012032A (es) 2023-12-08
JP2024517087A (ja) 2024-04-19
EP4323002A4 (en) 2025-04-16
PH12023552841A1 (en) 2024-05-20
WO2022221239A1 (en) 2022-10-20
US20240182598A1 (en) 2024-06-06
AU2022256389A1 (en) 2023-11-30
CL2023003033A1 (es) 2024-03-08
IL307445A (en) 2023-12-01
CA3216642A1 (en) 2022-10-20
EP4323002A1 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
SA522432691B1 (ar) المركبات الحلقية الماكروية وطرق العلاج المرتبطة بها
BR112018014222A2 (pt) método de tratamento da glomerulopatia c3
MX2020011465A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
MX2023009681A (es) Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon.
EA201992220A1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
EP4292588A3 (en) Administration of deuterated cftr potentiators
EA201370071A1 (ru) Способы и композиции для лечения рака легких
BR112017016378A2 (pt) composições da pró-droga de fumarato de monometila
EA201891853A1 (ru) Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3
AR101740A1 (es) Terapia de combinación y composiciones
NZ754676A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
IN2014DN03077A (cg-RX-API-DMAC7.html)
BR112018070946A2 (pt) administração de um construto biespecífico que se liga a cd33 e cd3 para uso em um método para o tratamento de leucemia mieloide
JOP20210245A1 (ar) طرق لعلاج الداء النشواني من النوع خفيف السلسلة
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
CO2022014499A2 (es) Moduladores de nlrp3
DK4058474T3 (da) Sammensætninger og fremgangsmåder til behandling af egfr-positive kræftformer
MX2021008941A (es) Moduladores gpr35.
CO2022001354A2 (es) Métodos para tratar o prevenir la atrofia muscular espinal
MX2025008017A (es) Uso de moduladores del receptor gabaa para el tratamiento del dolor
MX2022005032A (es) Terapia secuencial anti cumulo de diferenciacion 19 (cd19).
EA201200428A1 (ru) Композиция и способ для лечения ожирения
MX2021008507A (es) Moleculas que se unen al receptor leucocitario similar a inmunoglobulina subfamilia b miembro 3 (lilrb3) y usos para las mismas.
CL2023003033A1 (es) Composiciones y métodos para el tratamiento de la miastenia gravis pediátrica.